These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11335786)

  • 21. Design, synthesis, and anticancer activity of phosphonic acid diphosphate derivative of adenine-containing butenolide and its water-soluble derivatives of paclitaxel with high antitumor activity.
    Moosavi-Movahedi AA; Hakimelahi S; Chamani J; Khodarahmi GA; Hassanzadeh F; Luo FT; Ly TW; Shia KS; Yen CF; Jain ML; Kulatheeswaran R; Xue C; Pasdar M; Hakimelahi GH
    Bioorg Med Chem; 2003 Oct; 11(20):4303-13. PubMed ID: 13129566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. D-α-tocopherol polyethylene glycol succinate-based redox-sensitive paclitaxel prodrug for overcoming multidrug resistance in cancer cells.
    Bao Y; Guo Y; Zhuang X; Li D; Cheng B; Tan S; Zhang Z
    Mol Pharm; 2014 Sep; 11(9):3196-209. PubMed ID: 25102234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and evaluation of anticancer activity of BOC26P, an ortho-aryl chalcone sodium phosphate as water-soluble prodrugs in vitro and in vivo.
    Zhu C; Wang R; Zheng W; Chen D; Yue X; Cao Y; Qin W; Sun H; Wang Y; Liu Z; Li B; Du J; Bu X; Zhou B
    Biomed Pharmacother; 2017 Dec; 96():551-562. PubMed ID: 29032339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice.
    Prijovich ZM; Chen BM; Leu YL; Chern JW; Roffler SR
    Br J Cancer; 2002 May; 86(10):1634-8. PubMed ID: 12085215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy.
    Shan L; Zhuo X; Zhang F; Dai Y; Zhu G; Yung BC; Fan W; Zhai K; Jacobson O; Kiesewetter DO; Ma Y; Gao G; Chen X
    Theranostics; 2018; 8(7):2018-2030. PubMed ID: 29556370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer.
    Boven E; Venema-Gaberscek E; Erkelens CA; Bissery MC; Pinedo HM
    Ann Oncol; 1993 Apr; 4(4):321-4. PubMed ID: 8100146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer.
    Kim JE; Park YJ
    Int J Nanomedicine; 2017; 12():645-658. PubMed ID: 28176896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, characterization and in vitro cytotoxicity studies of a macromolecular conjugate of paclitaxel bearing oxytocin as targeting moiety.
    Cavallaro G; Maniscalco L; Campisi M; Schillaci D; Giammona G
    Eur J Pharm Biopharm; 2007 May; 66(2):182-92. PubMed ID: 17182230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
    Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
    J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of two kinds of docetaxel-vitamin E prodrugs: In vitro evaluation and in vivo antitumor activity.
    Wang J; Xue P; Zhou J; Li L; Xu L; Wang Y
    Int J Pharm; 2016 May; 505(1-2):352-60. PubMed ID: 27085643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
    Friedlos F; Davies L; Scanlon I; Ogilvie LM; Martin J; Stribbling SM; Spooner RA; Niculescu-Duvaz I; Marais R; Springer CJ
    Cancer Res; 2002 Mar; 62(6):1724-9. PubMed ID: 11912146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Balancing the efficacy vs. the toxicity of promiscuous natural products: Paclitaxel-based acid-labile lipophilic prodrugs as promising chemotherapeutics.
    Haider S; Penfornis P; Claudio PP; McChesney JD; Chittiboyina AG
    Eur J Med Chem; 2022 Jan; 227():113891. PubMed ID: 34656042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts.
    Houba PH; Boven E; Erkelens CA; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Br J Cancer; 1998 Dec; 78(12):1600-6. PubMed ID: 9862570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
    Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes.
    Safavy A; Raisch KP; Khazaeli MB; Buchsbaum DJ; Bonner JA
    J Med Chem; 1999 Nov; 42(23):4919-24. PubMed ID: 10579854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-specific novel taxoid-monoclonal antibody conjugates.
    Ojima I; Geng X; Wu X; Qu C; Borella CP; Xie H; Wilhelm SD; Leece BA; Bartle LM; Goldmacher VS; Chari RV
    J Med Chem; 2002 Dec; 45(26):5620-3. PubMed ID: 12477344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity of doxorubicin in combination with docetaxel against human breast cancer xenografts.
    Egawa T; Kubota T; Suto A; Otani Y; Furukawa T; Saikawa Y; Watanabe M; Kumai K; Kitajima M
    In Vivo; 2003; 17(1):23-8. PubMed ID: 12655785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles.
    Zhigaltsev IV; Winters G; Srinivasulu M; Crawford J; Wong M; Amankwa L; Waterhouse D; Masin D; Webb M; Harasym N; Heller L; Bally MB; Ciufolini MA; Cullis PR; Maurer N
    J Control Release; 2010 Jun; 144(3):332-40. PubMed ID: 20202473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.
    Chen X; Zhang XY; Shen Y; Fan LL; Ren ML; Wu YP
    Oncotarget; 2016 Dec; 7(50):83451-83461. PubMed ID: 27825139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.